Commercialisation director joins Edinburgh BioQuarter

Life sciences entrepreneur Michael Capaldi joins Scotland\'s flagship project

Michael Capaldi, scientist and life sciences entrepreneur, has been named as director of commercialisation for the Edinburgh BioQuarter – Scotland’s flagship project for the life sciences sector.

Capaldi will lead a team of up to 15 people to progress a £12m commercialisation project that will bridge the gap between industry and research.

Capaldi has more than 26 years’ experience in the pharmaceutical and life sciences industries within the UK, Europe and the US.

You may also like

Research & Development

University of Edinburgh to collaborate with Galapagos on cancer therapies

Two-year partnership with plans to extend
Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing

New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
Manufacturing

Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility

The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market
Research & Development

VoxCell BioInnovation and adMare partner to validate bioprinted vascularised cancer tissue models for antibody therapy development

The pair have announced a research collaboration using VoxCell's human-relevant bioprinted vascularised cancer tissue models to validate a novel antibody-based immune-modulating therapy, as the FDA advances plans to reduce animal testing for monoclonal antibodies through New Approach Methodologies
Subscribe now